WinstonWınston
Back
ConvaTec Group logo

ConvaTec Group

CTEC.L
56
Medical - Instruments & Supplies · Healthcare
Exchange
London Stock Exchange
Winston Score
56
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Good
Growth
Mixed
Cash Flow
Strong
Stability
Good
Valuation
Good
Dividends
Good

Winston Score History

The full picture

ConvaTec is a British medical supplies company that makes products for people with long-term health conditions. Its main products include wound dressings, ostomy bags (pouches worn by people who have had bowel surgery), devices that deliver medicine under the skin, and products that manage urinary and bowel issues. It sells mostly to hospitals, clinics, and home care patients across the world.

The company earns money by selling these consumable medical supplies, meaning customers need to reorder them regularly, which creates a steady and predictable revenue stream. ConvaTec operates in over 100 countries, with strong sales in North America and Europe, and generates roughly $2 billion in annual revenue. Its moat comes from the sticky nature of its products — patients and clinicians rarely switch brands once trained on a specific device or dressing system. The key growth driver is an aging global population that increases demand for chronic care products, while the main risk is pricing pressure from hospital purchasing groups and competition from larger rivals like Coloplast and Hollister.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+3.6% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-46.8% YoY

YoY Growth Rate

Earnings declining

Insider Activity

22.3%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~8 months

£142M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

ConvaTec Group has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
54.3%
Healthy — 54.3% gross margin
Profit after running costs
Operating Margin
14.5%
Healthy — 14.5% operating margin
Return on the money invested
ROCE
13.0%
Good — 13.0% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+5.6%
Slow sales growth (+5.6% YoY)
Profit growth
EPS YoY
-40.1%
Earnings shrinking (-40.1% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
308%
Turns 308% of profit into real cash
Spare cash per sale
FCF Margin
7.7%
Modest free cash flow (7.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.16
Elevated debt (1.16)
Covers its interest
Interest Cover
5.34x
Adequate interest coverage (5.3x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
35.6x
no trend
Pricey — P/E 35.6

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year
P/E vs Forward
+23.1
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (35.6 → 12.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
2.33%
no trend
Moderate income — 2.33% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record
Dividend Growth
+4.7%
no trend
Dividend growing modestly (4.7% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial